Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells

被引:74
作者
Dürkop, H [1 ]
Foss, HD [1 ]
Demel, G [1 ]
Klotzbach, H [1 ]
Hehn, C [1 ]
Stein, H [1 ]
机构
[1] Free Univ Berlin, Inst Pathol, D-12200 Berlin, Germany
关键词
D O I
10.1182/blood.V93.2.617.402k14_617_623
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The tumor necrosis factor (TNF) receptor-associated factor 1 (TRAF1) is a member of the recently defined TRAF family. It takes part in the signal transduction of the TNF receptor 2 (TNFR2). the lymphotoxin-beta receptor (LT-beta R), CD40, CD30, and LMP1; is induced by LMP1 in vitro; and protects lymphoid cells from apoptosis. To identify the cells in which TRAF1 is active in vivo, we studied TRAF1 transcripts in normal lymphoid tissue, in Epstein-Barr virus (EBV)-induced lymphoproliferations. and in malignant lymphomas with special reference to those that overexpress the cytokine receptor CD30 and CD40 of the TNF receptor family at the single-cell level using a radioactive in situ hybridization. In normal lymphoid tissue, TRAF1 message proved to be absent from all resting B and T cells as well as from macrophages and accessory cells (follicular dendritic cells and interdigitating cells) and present in few perifollicular and intrafollicular lymphoid blasts. In contrast, there was a high and consistent TRAF1 overexpression in EBV-induced lymphoproliferations and Hodgkin's disease. Nearly all nonHodgkin's lymphoma show low or no TRAF1 expression. Only some cases of diffuse large B-cell lymphoma showed a moderate to high TRAF1 signal. Several of the latter cases were EBV+. These data confirm that TRAF1 is an inducible molecule and indicates its deregulation in the mentioned disorders with the potential of a blockage of the apoptotic pathway. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:617 / 623
页数:7
相关论文
共 38 条
[1]
Baker SJ, 1996, ONCOGENE, V12, P1
[2]
Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells [J].
Bargou, RC ;
Emmerich, F ;
Krappmann, D ;
Bommert, K ;
Mapara, MY ;
Arnold, W ;
Royer, HD ;
Grinstein, E ;
Greiner, A ;
Scheidereit, C ;
Dörken, B .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :2961-2969
[3]
A NOVEL PROTEIN THAT INTERACTS WITH THE DEATH DOMAIN OF FAS/APO1 CONTAINS A SEQUENCE MOTIF RELATED TO THE DEATH DOMAIN [J].
BOLDIN, MP ;
VARFOLOMEEV, EE ;
PANCER, Z ;
METT, IL ;
CAMONIS, JH ;
WALLACH, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (14) :7795-7798
[4]
EXPRESSION OF FUNCTIONAL CD30 ANTIGEN ON REED-STERNBERG CELLS AND HODGKINS-DISEASE CELL-LINES [J].
CARBONE, A ;
GLOGHINI, A ;
GATTEI, V ;
ALDINUCCI, D ;
DEGAN, M ;
DEPAOLI, P ;
ZAGONEL, V ;
PINTO, A .
BLOOD, 1995, 85 (03) :780-789
[5]
CHEN CW, 1994, FOREST SCI, V40, P267
[6]
FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS [J].
CHINNAIYAN, AM ;
OROURKE, K ;
TEWARI, M ;
DIXIT, VM .
CELL, 1995, 81 (04) :505-512
[7]
IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES) [J].
CORDELL, JL ;
FALINI, B ;
ERBER, WN ;
GHOSH, AK ;
ABDULAZIZ, Z ;
MACDONALD, S ;
PULFORD, KAF ;
STEIN, H ;
MASON, DY .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) :219-229
[8]
Devergne O, 1996, MOL CELL BIOL, V16, P7098
[9]
FISCHER P, 1988, BLOOD, V72, P234
[10]
HARRIS NL, 1994, BLOOD, V84, P1361